Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

THR 317

Drug Profile

THR 317

Alternative Names: Anti-placental growth factor monoclonal antibody; Anti-PlGF; Anti-PlGF monoclonal antibody; R-7334; RG 7334; RO-5323441; TB 403; THR-317; αPlGF

Latest Information Update: 22 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioInvent International; ThromboGenics
  • Developer BioInvent International; Oncurious; Oxurion
  • Class Anti-inflammatories; Antineoplastics; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Placenta growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Medulloblastoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diabetic macular oedema; Diabetic retinopathy; Retinal telangiectasis
  • Phase I/II Medulloblastoma
  • Discontinued Age-related macular degeneration; Glioblastoma; Liver cancer; Solid tumours

Most Recent Events

  • 20 Aug 2019 Efficacy data and adverse events data from a phase IIa trial in Diabetic macular oedema released by Oxurion
  • 18 Jul 2019 Oxurion completes a phase II trial in Diabetic retinopathy and Diabetic macular oedema (Combination therapy) in Belgium, France, Germany, Slovakia, Spain, Switzerland, United Kingdom (Intravitreous) (NCT03499223)
  • 11 Apr 2019 Discontinued - Phase-I for Age-related macular degeneration (In volunteers) in Denmark (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top